# A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

> **NCT04024761** · PHASE1 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 50 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Myeloproliferative Neoplasm
- Juvenile Myelomonocytic Leukemia

## Interventions

- **BIOLOGICAL:** CIML NK
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04024761
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-31
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024761, "A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04024761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*